US20240342222
2024-10-17
Human necessities
A61K35/37
Compositions are provided that incorporate extracts from human feces, aimed at modifying or supplementing a subject's colon microbiota. These compositions can be utilized for treating various diseases or conditions affecting the colon. They may contain specified percentages of non-living material in relation to biological material, ensuring a diverse microbial composition.
The rise of Clostridium difficile infection (CDI) has become a significant health concern, particularly due to its increasing incidence and severity. This bacterial infection is often linked to antibiotic use, leading to a disruption of normal gut microbiota and resulting in recurrent infections. Risk factors for CDI include older age, antibiotic usage, and underlying conditions such as inflammatory bowel disease.
Healthy intestinal microbiota play a crucial role in protecting against CDI. Disruption of these microbial communities due to antibiotic treatment is a major contributor to the recurrence of CDI. Research has shown that restoring normal gut microbiota can help reduce the incidence of recurrent infections, emphasizing the need for effective therapeutic approaches.
Fecal microbiota transplantation (FMT) has emerged as a promising treatment for recurrent CDI, demonstrating a high success rate in restoring normal gut flora. Despite its effectiveness, the procedure faces practical challenges that limit its availability, including concerns about donor screening, preparation, and patient acceptance.
The compositions detailed include various combinations of gut bacteria from different phyla, such as Bacteroidetes and Firmicutes. These formulations can be designed for oral administration and may include pharmaceutically acceptable carriers. The goal is to create a viable alternative to traditional FMT procedures, making it more accessible for patients suffering from recurrent CDI.